News Posts List

Wyeth Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved TORISEL (temsirolimus) for patients with advanced renal cell carcinoma (RCC).   TORISEL is the first targeted renal cancer therapy proven to extend median overall survival versus interferon-alpha, an active comparator, in this patient population.

Renal cell carcinoma accounts for approximately 85 percent of kidney cancers.   The American Cancer Society estimates that 51,190 new cases of kidney cancer will be diagnosed this year, and more than 40 percent of these patients are initially diagnosed with advanced disease.   TORISEL is the only marketed cancer therapy that specifically inhibits the mTOR (mammalian target of rapamycin) kinase, a key protein in cells that regulates cell proliferation, cell growth and cell survival.   Wyeth anticipates that TORISEL will be available to patients in July 2007.

Source: Wyeth press release